Evaxion A/S (NasdaqCM: EVAX)
Health Care · Biotechnology · DK
$3.26
-1.51% today · +3.2% 1Y
Evaxion A/S (NasdaqCM: EVAX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $27.61M and employs 46 people.
Over the last twelve months the share price has gained 3.2%, trading between 2.52 and 12.15.
Tweenvest scores Evaxion A/S across four factors: quality 28/100, value 66/100. Its strongest factor is value.
EVAX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $27.61M
- Revenue (TTM)
- $7.49M
- P/E
- —
- EPS
- -1.09
- Dividend yield
- —
- Beta (5Y)
- 0.25
- 52-week high
- $12.15
- 52-week low
- $2.52
- Avg volume (3M)
- —
- Shares outstanding
- 8.34M
- Employees
- 46
- Next earnings
- —
About Evaxion A/S
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
- ISIN
- US29970R3030
- Founded
- 2008
- Listed since
- Feb 5, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.90 | -2.47% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.